RNA drug specialist Moderna smashed the record for an initial public offering (IPO) in the US on Friday, raising a whopping $604 million, although its shares retreated 19% after the debut......
Moderna Therapeutics, which is pushing a pipeline of mRNA candidates into phase 2 trials, now has a manufacturing plant ready to advance its highly anticipated program.
On the heels of a massive $500 million round, Moderna has picked up another $125 million in preferred equity as it expands its mRNA cancer vaccine partnership with Merck.